While companies have started to pass input cost rise to consumers, inflation, according to G Chokkalingam, founder and head of research at Equinomics Research has not become a major issue yet.
Vijaya Diagnostic Centre was quoting higher for the eight straight trading day, soaring 25 per cent during the period.
For the March quarter of FY26, Marico reported an 18.26 per cent Y-o-Y rise in consolidated net profit to ₹408 crore. Its consolidated revenue from operations stood at ₹3,333 crore.
The consumer sector now faces a delicate balance between sustaining demand and protecting profitability, with inflation once again emerging as the key swing factor
Its consolidated revenue from operations in the fourth quarter stood at ₹3,333 crore compared to ₹2,730 crore in the year-ago period
Kunal Shah Senior Technical Analyst at Mirae Asset Sharekhan believes that Nestle India has given a decisive breakout on the weekly chart, and could potentially rally to ₹1,500-mark on the upside.
Easing geopolitical tensions and softening input costs are lifting overall sentiment in the consumer goods space, said analyst at Mirae Asset Sharekhan.
Marico in an exchange filing said that its revenue in Q4FY26 grew in the low 20s on a year-on-year (Y-o-Y) basis, led by pricing, its hair oil and international business.
Sustained volatility in crude prices could create pressure on gross margins across the FMCG sector, warn analysts.
YES Securities believe Marico stock offers an attractive risk-reward for investors, with over 13 per cent EPS CAGR potential over FY25-28E
Nomura's top picks include Britannia and Titan. It also prefers Marico, Tata Consumer, Godrej Consumer, Asian Paints and United Spirits
Concerns over rising inflation stemming from potential energy supply disruptions and rationing prompted investors to book profits, while FII outflows added to the market pressure, said Geojit.
Nifty FMCG index dropped 2.4 per cent today as commodity prices rise amid Iran war. Nomura warned that higher input costs could hurt margins of HUL, GCPL and Colgate Palmolive in Q1FY27
Leading fastmoving consumer goods (FMCG) companies expect volumedriven growth to take centre stage in the next fiscal year, supported by easing inflation and stable commodity prices that have begun to ease pressure on margins. In the December quarter, leading FMCG companies reported mid- to high single-digit volume growth. On their latest earnings calls, the industry captains said the operating environment is turning more favourable after several quarters of volatility. Key inputs such as edible oils, wheat, copra and surfactants softened, and with macroeconomic tailwinds including GST rationalisation, higher MSPs and a healthy crop season, FMCG makers anticipate sustained demand recovery. Most players have already taken calibrated price hikes earlier in the fiscal year and now expect growth to be led by volumes rather than pricing. Some companies indicated they may pass on some benefits of lower input costs to consumers through offers, increased grammage or selective discounts, ev
Marico's strong Q3 performance, rising premium product share and steady volume outlook have lifted investor sentiment, though volatility in Copra and risks abroad remain key concerns
For Q4, the brokerage expects Marico to lead the HPC segment with around 20 per cent sales growth, followed by 9-10 per cent growth for Dabur India and Godrej Consumer Products
With input cost easing and margin pressure subsiding, the management expects progressive improvement in operating profit growth rates over the coming quarters.
Om Mehra, tech analyst at SAMCO Securities explains that Britannia is trading in a well-defined rectangular range, or more precisely, a Darvas Box repeatedly finding support near the lower boundary.
Stocks to Watch today, February 5, 2026: Medanta, JSW Cement, Cummins India, Emcure Pharma, Bajaj Finserv, Metropolis, Emami, Lupin, and NHPC are among the top stocks to watch today
Marico has signed definitive agreements to acquire a majority stake in digital-first wellness brand Cosmix Wellness, valuing the company at ₹375 crore and strengthening its health portfolio